Answers are grounded in this paper and cite their sources.
Background: Data on cervical cytological abnormalities in women with inflammatory bowel disease (IBD) are inconsistent. We compared their prevalence in women with and without IBD. Methods: In this retrospective single-centre analysis of electronic medical records (2022–2024), women with Crohn’s disease (CD) or ulcerative colitis (UC) were compared with 141 women treated at a gynaecology outpatient clinic. Cytology was classified exclusively using the Bethesda System (abnormal = ASC-US or worse; “Pap II” inflammation = normal). Results: Of 301 women with IBD, 280 (141 CD, 139 UC) had evaluable cytology. The most recent cytology assessment was abnormal in 4/280 women with IBD (1.4%) versus 13/141 controls (9.2%; OR 0.14, 95% CI 0.05–0.45); a current or historical abnormality was identified in 12/280 women with IBD (4.3%) versus 13/141 controls (9.2%; OR 0.44, 95% CI 0.20–0.99; p = 0.051). CD and UC did not differ, and no clinical or treatment variable was associated with abnormality (12 events). hrHPV testing was documented in 15.7% of women with IBD (controls 85.8%). Conclusions: Abnormal cytology was infrequent in this closely monitored IBD cohort and numerically lower than in controls; however, the controls comprised a selected group, HPV testing differed between groups, and events were few, so an increased risk cannot be excluded. Regular gynaecological surveillance remains essential.
No takes yet. Share an insight, caveat, or question.
Tulewicz-Marti et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: